Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-08-13

Clinical Trial Update: A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) [Phase 1]

View source ↗

Summary

Completed Phase 1 study evaluating SP-02L in patients with relapsed or refractory Peripheral T-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SP-02L

Snippet

Sponsor: Solasia Pharma K.K. | Conditions: Peripheral T-cell Lymphoma | Phase 1 | Status: COMPLETED